Testing effectiveness (Phase 2)Study completedNCT03519412
What this trial is testing
Pembrolizumab in MMR-Proficient Metastatic Colorectal Cancer Pharmacologically Primed to Trigger Hypermutation Status
Who this might be right for
Colorectal NeoplasmsMicrosatellite Instability
IFOM ETS - The AIRC Institute of Molecular Oncology 107